Expert Opinion on Emerging Drugs

851 papers and 14.8k indexed citations i.

About

The 851 papers published in Expert Opinion on Emerging Drugs in the last decades have received a total of 14.8k indexed citations. Papers published in Expert Opinion on Emerging Drugs usually cover Molecular Biology (187 papers), Oncology (169 papers) and Pulmonary and Respiratory Medicine (137 papers) specifically the topics of Lung Cancer Treatments and Mutations (29 papers), Chronic Lymphocytic Leukemia Research (27 papers) and HER2/EGFR in Cancer Research (26 papers). The most active scholars publishing in Expert Opinion on Emerging Drugs are Paolo Martelletti, Cesare Gridelli, Francis J. Giles, Christian Guilleminault and Gordon S. Lynch.

In The Last Decade

Fields of papers published in Expert Opinion on Emerging Drugs

Since Specialization
EngineeringComputer SciencePhysics and AstronomyMathematicsEarth and Planetary SciencesEnergyEnvironmental ScienceMaterials ScienceChemical EngineeringChemistryAgricultural and Biological SciencesVeterinaryDecision SciencesArts and HumanitiesBusiness, Management and AccountingSocial SciencesPsychologyEconomics, Econometrics and FinanceHealth ProfessionsDentistryMedicineBiochemistry, Genetics and Molecular BiologyNeuroscienceNursingImmunology and MicrobiologyPharmacology, Toxicology and Pharmaceutics

This network shows the specialization of papers published in Expert Opinion on Emerging Drugs. Nodes represent fields, and links connect fields that are likely to share authors.

Countries where authors publish in Expert Opinion on Emerging Drugs

Since Specialization
Total citations of papers

This map shows the geographic distribution of research published in Expert Opinion on Emerging Drugs. It shows the number of citations received by papers published by authors working in each country. You can also color the map by specialization and compare the number of papers published in Expert Opinion on Emerging Drugs with the expected number of papers based on a country's size and research output (numbers larger than one mean the country's share of papers is larger than expected).

Rankless by CCL
2025